GlucoTrack Forms Patient Advisory Board Of Leading Diabetes Advocates To Incorporate Patient Insights Into Development Of Long-Term Implantable Continuous Blood Glucose Monitor

Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the formation of a Patient Advisory Board (PAB) comprised of leading patient voices and advocates within the diabetes community.

Following the successful completion of the Company's first-in-human clinical study, the PAB includes individuals with firsthand experiences and understanding of the impact diabetes management has on daily living. Establishing the PAB aims to keep patients' insights at the forefront of Glucotrack's development plans for its long-term implantable Continuous Blood Glucose Monitor (CBGM).